Working… Menu
Trial record 1 of 5 for:    pfizer | Recruiting, Not yet recruiting Studies | bladder cancer
Previous Study | Return to List | Next Study

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04165317
Recruitment Status : Recruiting
First Posted : November 15, 2019
Last Update Posted : July 1, 2021
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 3, 2024
Estimated Study Completion Date : December 2, 2026